Increases in Natriuretic Peptides Precede Heart Failure Hospitalization in Patients With a Recent Coronary Event and Type 2 Diabetes Mellitus-Reference-Cited by-同舟云学术

Increases in Natriuretic Peptides Precede Heart Failure Hospitalization in Patients With a Recent Coronary Event and Type 2 Diabetes Mellitus

Published:2017-10-17 Issue:16 Volume:136 Page:1560-1562
ISSN:0009-7322
Container-title:Circulation
language:en
Short-container-title:Circulation

Author:

Wolsk Emil¹,Claggett Brian¹,Diaz Rafael¹,Dickstein Kenneth¹,Gerstein Hertzel C.¹,Køber Lars¹,Lawson Francesca C.¹,Lewis Eldrin F.¹,Maggioni Aldo P.¹,McMurray John J. V.¹,Probstfield Jeffrey L.¹,Riddle Matthew C.¹,Solomon Scott D.¹,Tardif Jean-Claude¹,Pfeffer Marc A.¹

Affiliation:

1. From Division of Cardiovascular Medicine, Brigham and Women’s Hospital, Harvard Medical School, Boston, MA (E.W., B.C., E.F.L., S.D.S., M.A.P.); Department of Cardiology, Rigshospitalet, Copenhagen, Denmark (E.W., L.K.); Estudios Clínicos Latinoamérica, Rosario, Argentina (R.D.); University of Bergen, Stavanger University Hospital, Norway (K.D.); Division of Endocrinology & Metabolism, McMaster University, Hamilton, Ontario, Canada (H.C.G.); Sanofi US, Bridgewater, NJ (F.C.L.); Research Center...

Publisher

Ovid Technologies (Wolters Kluwer Health)

Subject

Physiology (medical),Cardiology and Cardiovascular Medicine

Link

https://www.ahajournals.org/doi/pdf/10.1161/CIRCULATIONAHA.117.029503

Reference5 articles.

1. Mortality following a cardiovascular or renal event in patients with type 2 diabetes in the ALTITUDE trial

2. A history of diabetes predicts outcomes following myocardial infarction: an analysis of the 28 771 patients in the High-Risk MI Database

3. Role of Biomarkers for the Prevention, Assessment, and Management of Heart Failure: A Scientific Statement From the American Heart Association

4. Lixisenatide in Patients with Type 2 Diabetes and Acute Coronary Syndrome

5. Rationale, design, and baseline characteristics in Evaluation of LIXisenatide in Acute Coronary Syndrome, a long-term cardiovascular end point trial of lixisenatide versus placebo

Cited by 16 articles. 订阅此论文施引文献订阅此论文施引文献，注册后可以免费订阅5篇论文的施引文献，订阅后可以查看论文全部施引文献

1. Outpatient Worsening Among Patients With Mildly Reduced and Preserved Ejection Fraction Heart Failure in the DELIVER Trial;Circulation;2023-11-28

2. Biomarker Changes Associated With Both Dulaglutide and Cardiovascular Events in the REWIND Randomized Controlled Trial: A Nested Case-Control Post Hoc Analysis;Diabetes Care;2023-03-10

3. Effect of lixisenatide on natriuretic peptides in people with type 2 diabetes and recent acute coronary syndrome: The ELIXA trial;Diabetes, Obesity and Metabolism;2023-01-03

4. Saudi Heart Association Position Statement on the Use of Biomarkers for the Management of Heart Failure and Acute Coronary Syndrome;Journal of the Saudi Heart Association;2022-08-10

5. Protein Biomarkers and Cardiovascular Outcomes in People With Type 2 Diabetes and Acute Coronary Syndrome: The ELIXA Biomarker Study;Diabetes Care;2022-07-11